Parameter
| Biomarker | Fibroblast growth factor-21 (FGF-21) | Full name | Fibroblast growth factor-21 | Molecular Type | Cytokines |
|---|---|---|---|---|---|
| Molecular Formula | Human FGF-21: C₁₀₈₃H₁697N₂97O₃21S₇ | Molecular Weight | ~22.1 kDa | Core Functional Dimensions | Metabolic regulation, anti-inflammatory |
| Disease | Metabolic Associated Fatty Liver Disease (MASLD) | Disease Subtypes | / | ||
| Organ | Liver | Test Sample / Technology Platform | Serum (ELISA, mass spectrometry) | ||
| Pathobiological Mechanisms | Hepatocyte stress secreted FGF-21, which was higher in NASH patients (SMD=1.30), reflecting metabolic disorder and inflammation | ||||
| Clinical Availability Status | In the research phase, a phase Ⅲ clinical trial (efruxifermin) is ongoing | ||||
| Notes and Dynamics | FGF-21 is a potential therapeutic target for NASH, and the clinical research progress of FGF-21 analogues is worthy of attention | ||||